All News about Maxcyte Inc
![](https://cdn.benzinga.com/files/images/story/2023/05/11/disney_-logo.jpg?width=1200&height=800&fit=crop)
![](/next-assets/images/schema-image-default.png)
Recap: MaxCyte Q1 Earnings
May 10, 2023
Via Benzinga
![](https://ml.globenewswire.com/media/8f0f0d48-fc4f-4d03-ac70-f4d096a780bd/small/maxcyte-logo-600x600-png.png)
![](https://ml.globenewswire.com/media/8f0f0d48-fc4f-4d03-ac70-f4d096a780bd/small/maxcyte-logo-600x600-png.png)
From MaxCyte, Inc
Via GlobeNewswire
![](/next-assets/images/schema-image-default.png)
Looking Into MaxCyte's Return On Capital Employed
March 16, 2023
Via Benzinga
![](/next-assets/images/schema-image-default.png)
MaxCyte's Earnings: A Preview
March 14, 2023
Via Benzinga
![](https://investorplace.com/wp-content/uploads/2022/06/biotechnologyepzm1600.png)
![](https://ml.globenewswire.com/media/8f0f0d48-fc4f-4d03-ac70-f4d096a780bd/small/maxcyte-logo-600x600-png.png)
From MaxCyte, Inc
Via GlobeNewswire
![](https://ml.globenewswire.com/media/8f0f0d48-fc4f-4d03-ac70-f4d096a780bd/small/maxcyte-logo-600x600-png.png)
MaxCyte Appoints Douglas Swirsky as Chief Financial Officer
March 27, 2023
From MaxCyte, Inc
Via GlobeNewswire
MaxCyte Earnings Perspective: Return On Capital Employed
December 14, 2022
Via Benzinga
![](https://cdn.benzinga.com/files/images/story/2022/04/13/aapharma_1.png?width=1200&height=800&fit=crop)
MaxCyte Expects Q1 Sales To Beat Expectations, CFO Resigns
April 13, 2022
Via Benzinga
![](https://ml.globenewswire.com/media/8f0f0d48-fc4f-4d03-ac70-f4d096a780bd/small/maxcyte-logo-600x600-png.png)
![](https://cdn.benzinga.com/files/images/story/2023/earnings_image_170.jpeg?width=1200&height=800&fit=crop)
![](https://ml.globenewswire.com/media/8f0f0d48-fc4f-4d03-ac70-f4d096a780bd/small/maxcyte-logo-600x600-png.png)
![](https://ml.globenewswire.com/media/8f0f0d48-fc4f-4d03-ac70-f4d096a780bd/small/maxcyte-logo-600x600-png.png)
![](https://investorplace.com/wp-content/uploads/2021/08/penny-stocks-1600.jpg)
![](https://ml.globenewswire.com/media/8f0f0d48-fc4f-4d03-ac70-f4d096a780bd/small/maxcyte-logo-600x600-png.png)
![](https://ml.globenewswire.com/media/8f0f0d48-fc4f-4d03-ac70-f4d096a780bd/small/maxcyte-logo-600x600-png.png)
![](https://investorplace.com/wp-content/uploads/2020/06/death-stocks-to-sell.jpg)
![](https://ml.globenewswire.com/media/8f0f0d48-fc4f-4d03-ac70-f4d096a780bd/small/maxcyte-logo-600x600-png.png)
![](https://ml.globenewswire.com/media/8f0f0d48-fc4f-4d03-ac70-f4d096a780bd/small/maxcyte-logo-600x600-png.png)
MaxCyte Reports Third Quarter 2022 Financial Results
November 09, 2022
From MaxCyte, Inc
Via GlobeNewswire
![](https://cdn.benzinga.com/files/images/story/2022/ep_us_feature_image_6062.jpeg?width=1200&height=800&fit=crop)
![](https://ml.globenewswire.com/media/8f0f0d48-fc4f-4d03-ac70-f4d096a780bd/small/maxcyte-logo-600x600-png.png)
MaxCyte to Participate in Upcoming Investor Conferences
November 02, 2022
From MaxCyte, Inc
Via GlobeNewswire
![](https://ml.globenewswire.com/media/8f0f0d48-fc4f-4d03-ac70-f4d096a780bd/small/maxcyte-logo-600x600-png.png)
From MaxCyte, Inc
Via GlobeNewswire
![](https://cdn.benzinga.com/files/images/story/2022/09/28/aapharma_13.png?width=1200&height=800&fit=crop)
![](https://ml.globenewswire.com/media/8f0f0d48-fc4f-4d03-ac70-f4d096a780bd/small/maxcyte-logo-600x600-png.png)
![](https://cdn.benzinga.com/files/images/story/2022/earnings_image_8343.jpeg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2022/ep_us_feature_image_4525.jpeg?width=1200&height=800&fit=crop)
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.